No Detail Found!

Mirabegron: a Novel and Promising Medical Expulsive Treatment for Ureteral Stones?.

Author(s)
Ahmet Urkmez Department of Urology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey
Emre Tokuc Department of Urology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey
Ramazan Topaktas Department of Urology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey
Aytac Sahin Department of Urology, Fatih Sultan Mehmet Research and Training Hospital, Istanbul, Turkey
OzgurH Yuksel Department of Urology, Bahcesehir University, VM Medical Park Hospital, Istanbul, Turkey
Abstract
Medical expulsive therapy (MET) is used especially in distal ureteral stones to reduce colics and decrease the number of endourological surgical interventions. A broad spectrum of agents can be used for the relaxation and the dilatation of the ureter, reducing the intraureteric pressure. Alfa-blockers, calcium channel blockers, phosphodiesterase (PDE) inhibitors, and spasmolytics have been shown as effective in clinical trials on urolithiasis. It is a fact that the urothelium itself, the interstitial cells and the ureteric smooth muscle, have B-beta-2 and beta-3 adrenoreceptors. Stimulation of these receptors results in relaxation of the ureter. A recent beta-3 agonist, mirabegron, is commonly used for overactive bladder nowadays. The mechanism of action is adrenergic agonism that affects with the storage phase of the bladder, without interfering the voiding phase, which is regulated by parasympathetic pathways, commonly muscarinic. Agonism of the beta-3 receptors in the ureter has been shown to decrease the intraluminal pressure. By this mechanism, mirabegron can be thought as an alternative MET agent. Acting through different pathways, and having low adverse effect profile, can be thought as the most striking advantages of mirabegron as a MET. In vitro and in vivo trials should be conducted to support this hypothesis.
Publication Details
Page(s) 73-74
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 29, Issue: 1, Year: 2019

Request the full text from PASTIC

References
TürkC,KnollT,SeitzC,SkolarikosA,ChappleC,McClintonS, 2017.Medical expulsive therapy for ureterolithiasis: The EAU recommendations in 2016,Eur Urol 71 504 -7
KroczakT,ScotlandKB,ChewB,PaceKT, 2017.Shockwave lithotripsy: tech-niques for improving outcomes,World J Urol 35 1341 -6
LimKT,KimYT,LeeTY,ParkSY, 2011.Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts,Korean J Urol 52 485 -8
CandaAE,TurnaB,CinarGM,NazliO, 2007.Physiology and pharmacology of the human ureter: Basis for current and future treatments,Urol Int 78 289 -98
WangH,ManLB,HuangGL,LiGZ,WangJW, 2016.Comparative efficacy of tamsulosin versus nifedipine for distal ureteral calculi: A meta-analysis,Drug Des Devel Ther 10 1257 -65
CoelhoA,Antunes-LopesT,GillespieJ,CvuzF, 2017.Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study,Neurourol Urodyn 36 1972 -80
MatsumotoR,OtsukaA,SuzukiT,ShinboH,NizunoT,KuritaY, 2013.Expression and functional role of 3 -adrenoceptors in the human ureter,Int J Urol 20 1007 -14
SebastianelliA,RussoGI,KaplanSA,Mc VaryKT,MoncadaI,GravasS, 2018.Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/ overactive bladder: Comparison with placebo and tolterodine,Int J Urol 25 196 -205
WanajoI,TomiyamaY,YamazakiY,KojimaM., 2011.Ureteral selectivity of intravenous beta-adrenoceptor agonists in pig model of acute ureteral obstruction: comparison of KUL-7211, a selective beta2/beta3 agonist, with isoproterenol,terbutaline, and CL-316243. Urology 77 e1 -6
MichelMC,GravasS. Safety, 2016.and tolerability of beta3- adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies,Expert Opin Drug Saf 15 647 -57
0

Citations

0

Downloads

103

Views